Risk of sudden unexplained death after use of dihydroartemisinin–piperaquine for malaria: a systematic review and Bayesian meta-analysis Xin Hui S Chan, MRCP, Yan Naung Win, MPH, Laura J Mawer, MBBChir, Jireh Y Tan, MS, Prof Josep Brugada, PhD, Prof Nicholas J White, FRS The Lancet Infectious Diseases Volume 18, Issue 8, Pages 913-923 (August 2018) DOI: 10.1016/S1473-3099(18)30297-4 Copyright © 2018 World Health Organization Terms and Conditions
Figure 1 Study selection DP=dihydroartemisinin–piperaquine. MSAT=mass screen and treat. IPT=intermittent preventive therapy. IST=intermittent screen and treat. SMC=seasonal malaria chemoprevention. PK=pharmacokinetic. The Lancet Infectious Diseases 2018 18, 913-923DOI: (10.1016/S1473-3099(18)30297-4) Copyright © 2018 World Health Organization Terms and Conditions
Figure 2 Number of individuals exposed to, and deaths after, dihydroartemisinin–piperaquine The Lancet Infectious Diseases 2018 18, 913-923DOI: (10.1016/S1473-3099(18)30297-4) Copyright © 2018 World Health Organization Terms and Conditions
Figure 3 Causes of death after dihydroartemisinin–piperaquine Data presented by age group and treatment indication. The Lancet Infectious Diseases 2018 18, 913-923DOI: (10.1016/S1473-3099(18)30297-4) Copyright © 2018 World Health Organization Terms and Conditions